Clinical Trial: NCT02413320
Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Priyanka Sharma |
| Information Provided By: | University of Kansas Medical Center |
| Last Update Posted: | 2021-05-10 |
Study Overview
Brief Summary
Evaluate if the two carboplatin containing chemotherapy regimens will reduce the growth of breast cancer cells in women with Stage I, II, or III triple negative breast cancer.
Official Title
Randomized Open Label Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel or Carboplatin Plus Paclitaxel Followed by Doxorubicin Plus Cyclophosphamide in Stage I-III Triple-negative Breast Cancer
Conditions
Triple-negative Breast Cancer
Intervention / Treatment
- Drug: Paclitaxel
- Drug: Carboplatin
- Drug: Doxorubicin
- Drug: Cyclophosphamide
- Drug: Docetaxel
Other Study ID Numbers
- 2015-IIT-Neoadjuvant-BRST-TNBC
Start Date
2015-07
Primary Completion Date (Actual)
2019-02-01
Study Completion Date (Actual)
2020-02-01
Enrollment (Actual)
101
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Priyanka Sharma |
| Information Provided By: | University of Kansas Medical Center |
| Last Update Posted: | 2021-05-10 |
Study Overview
Brief Summary
Evaluate if the two carboplatin containing chemotherapy regimens will reduce the growth of breast cancer cells in women with Stage I, II, or III triple negative breast cancer.
Official Title
Randomized Open Label Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel or Carboplatin Plus Paclitaxel Followed by Doxorubicin Plus Cyclophosphamide in Stage I-III Triple-negative Breast Cancer
Conditions
Triple-negative Breast Cancer
Intervention / Treatment
- Drug: Paclitaxel
- Drug: Carboplatin
- Drug: Doxorubicin
- Drug: Cyclophosphamide
- Drug: Docetaxel
Other Study ID Numbers
- 2015-IIT-Neoadjuvant-BRST-TNBC
Start Date
2015-07
Primary Completion Date (Actual)
2019-02-01
Study Completion Date (Actual)
2020-02-01
Enrollment (Actual)
101
Study Type
Interventional
Phase
Phase 2